Drug discovery pipelines are notorious for being costly, slow, and failure-prone, leading to AI and machine learning becoming more commonplace to accelerate progress and improve outcomes. Currently, ...

Monoclonal antibody (mAb) manufacturing must continually improve to keep up with increasing demands. To do this, biomanufacturers can deploy machine learning tools to augment traditional process ...